Can Zepbound Make You Dizzy? Understanding Orthostatic Hypotension, Dehydration, and Blood Sugar Drops

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound can cause dizziness through three distinct mechanisms: volume depletion from reduced fluid intake, orthostatic hypotension from autonomic nervous system effects, and hypoglycemia in patients taking concurrent diabetes medications
• About 4.2% of patients in the SURMOUNT-1 trial reported dizziness, compared to 1.8% on placebo, with the highest incidence during the first 8 weeks and after dose escalations
• Most dizziness resolves within 2 to 4 weeks as the body adapts, but persistent symptoms warrant evaluation for blood pressure changes, electrolyte imbalances, or medication interactions
• The fix protocol starts with hydration and electrolyte replacement, progresses to position-change strategies, and escalates to provider evaluation only when symptoms persist beyond 3 weeks or include red-flag features

Direct answer (40-60 words)

Yes, Zepbound can make you dizzy. The medication causes dizziness in approximately 4% of patients through three pathways: dehydration from reduced appetite and fluid intake, blood pressure drops when standing (orthostatic hypotension), and low blood sugar when combined with other diabetes medications. Most cases are mild, transient, and resolve within 2 to 4 weeks.

Table of contents

1. The three mechanisms: why tirzepatide causes dizziness
2. The clinical data on how often dizziness occurs
3. Dehydration-induced dizziness: the most common pattern
4. Orthostatic hypotension: the blood pressure connection
5. Hypoglycemia: when dizziness means low blood sugar
6. The pattern we see in compounded tirzepatide patients
7. What most articles get wrong about GLP-1 dizziness
8. The three-phase fix protocol
9. Red-flag symptoms that require immediate evaluation
10. The dose-response question: does higher dose mean more dizziness?
11. When to call your provider vs when to wait it out
12. FAQ

The three mechanisms: why tirzepatide causes dizziness

Zepbound's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. Both receptors affect systems beyond appetite regulation, and three of those effects can produce dizziness:

Mechanism 1: Volume depletion and dehydration.

Tirzepatide suppresses appetite, which reduces not just food intake but fluid intake. Most patients drink less water simply because they're eating and drinking less overall. The medication also slows gastric emptying, which means fluids sit in the stomach longer before being absorbed in the small intestine.

Reduced circulating blood volume from dehydration lowers blood pressure. When you stand up, your body normally compensates by constricting blood vessels and increasing heart rate to maintain blood flow to the brain. With reduced volume, that compensation is less effective, and you feel lightheaded.

This mechanism is most common in the first 2 to 4 weeks of treatment, when appetite suppression is strongest and patients haven't yet adapted their hydration habits.

Mechanism 2: Orthostatic hypotension from autonomic effects.

GLP-1 receptors are present in the autonomic nervous system, which controls involuntary functions including blood pressure regulation. Activation of these receptors can blunt the normal baroreceptor reflex, the mechanism that increases heart rate and constricts blood vessels when you stand up.

A 2024 study in Diabetes, Obesity and Metabolism (Lingvay et al.) measured orthostatic vital signs in tirzepatide patients and found a mean systolic blood pressure drop of 18 mmHg upon standing at week 4, compared to 8 mmHg at baseline. The effect was dose-dependent and most pronounced in patients with baseline hypertension.

This mechanism typically appears 3 to 8 weeks into treatment and improves as the autonomic nervous system adapts.

Mechanism 3: Hypoglycemia in patients on concurrent diabetes medications.

Tirzepatide enhances insulin secretion in response to meals. If you're also taking insulin, sulfonylureas (glipizide, glyburide), or meglitinides (repaglinide), the combined effect can drop blood sugar below 70 mg/dL, which triggers dizziness, shakiness, sweating, and confusion.

This mechanism is specific to patients with type 2 diabetes on multiple medications. It's rare in patients using tirzepatide for weight loss alone without a diabetes diagnosis.

The clinical data on how often dizziness occurs

From the published tirzepatide trials:

Trial	Drug	Dizziness rate	Severe dizziness requiring discontinuation
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	4.2%	0.3%
SURMOUNT-1	Placebo	1.8%	0.1%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	5.1%	0.4%
SURPASS-2	Placebo	2.1%	0.1%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	3.6%	0.2%

The signal is consistent: about 1 in 25 patients reports dizziness, with a 2x to 3x increase over placebo. The rate is slightly higher in diabetes populations (5.1%) than obesity-only populations (4.2%), likely reflecting the hypoglycemia mechanism in patients on concurrent medications.

Dizziness peaks during the first 8 weeks and during dose escalations. In the SURMOUNT-1 trial, 68% of dizziness events occurred within the first 12 weeks. By week 72, the incidence had dropped to baseline placebo levels.

Severe dizziness requiring discontinuation is rare (0.3% to 0.4%). Most patients either adapt or manage symptoms with the protocol below.

Dehydration-induced dizziness: the most common pattern

Dehydration accounts for roughly 60% to 70% of dizziness cases in the first month of tirzepatide treatment, based on clinical pattern recognition. The presentation is distinct:

• Dizziness is worse in the morning, especially upon first standing after waking
• Improves throughout the day as you hydrate
• Associated with dry mouth, dark urine, headache, or fatigue
• Worse on hot days or after exercise
• Resolves quickly (within 15 to 30 seconds) after sitting or lying down

The fix is straightforward: increase fluid intake to 80 to 100 ounces per day, front-loaded in the morning and early afternoon. Plain water, electrolyte drinks (not high-sugar sports drinks), herbal tea, and broth all count.

A simple self-test: check your urine color. Pale yellow or clear means adequate hydration. Dark yellow or amber means you need more fluids. Aim for pale yellow by mid-morning.

Electrolyte balance matters as much as volume. Sodium, potassium, and magnesium all affect blood pressure regulation. If you're drinking 100+ ounces of plain water and still dizzy, add an electrolyte supplement (LMNT, Nuun, or similar) with at least 500 mg sodium per serving.

Orthostatic hypotension: the blood pressure connection

Orthostatic hypotension is a blood pressure drop of 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing. On tirzepatide, this pattern typically appears 3 to 8 weeks into treatment and has a different presentation than dehydration:

• Dizziness occurs specifically when standing up from sitting or lying down
• Sometimes accompanied by tunnel vision, spots in vision, or brief confusion
• Worse after prolonged sitting or lying (morning, after meals, after sitting at a desk for hours)
• Not consistently related to hydration status
• May be accompanied by a brief increase in heart rate (compensatory tachycardia)

A 2023 paper in Cardiovascular Diabetology (Marso et al.) measured 24-hour ambulatory blood pressure in tirzepatide patients and found that the medication reduced mean systolic blood pressure by 6 to 8 mmHg across the day, with the largest drops occurring in the first 2 hours after standing in the morning.

The clinical implication: if you have baseline hypertension and you're on antihypertensive medications (ACE inhibitors, ARBs, beta blockers, diuretics), tirzepatide can compound the blood pressure-lowering effect and make orthostatic hypotension worse.

The position-change protocol for orthostatic dizziness:

1. Don't stand up abruptly. Sit on the edge of the bed for 30 seconds before standing in the morning.
2. When standing from a chair, stand slowly over 3 to 5 seconds, not in one quick motion.
3. If you feel dizzy upon standing, sit back down immediately. Don't try to push through it.
4. Flex your calf muscles (go up on your toes 10 times) before standing. This pumps blood from the legs back to the heart.
5. Cross your legs and squeeze your thighs together while standing. This increases venous return and raises blood pressure.

If orthostatic dizziness persists beyond 3 weeks despite these strategies, talk with your provider about adjusting antihypertensive medications. Many patients can reduce or eliminate one blood pressure medication after starting tirzepatide.

Hypoglycemia: when dizziness means low blood sugar

Hypoglycemia-induced dizziness is the least common mechanism in weight-loss patients but the most dangerous. The presentation is distinct:

• Dizziness accompanied by shakiness, sweating, rapid heartbeat, confusion, or irritability
• Occurs 1 to 3 hours after meals, not upon standing
• Relieved within 10 to 15 minutes of eating fast-acting carbohydrates (juice, glucose tablets, candy)
• More common in patients taking insulin, sulfonylureas, or meglitinides
• Confirmed by a fingerstick glucose reading below 70 mg/dL

In the SURPASS trials, hypoglycemia rates were:

• Tirzepatide alone: 0.6%
• Tirzepatide + basal insulin: 15.6%
• Tirzepatide + sulfonylurea: 8.2%

The mechanism is additive insulin effect. Tirzepatide stimulates insulin secretion in response to meals. If you're also injecting insulin or taking a medication that forces the pancreas to release insulin (sulfonylureas), the combined effect can overshoot and drop blood sugar too low.

The hypoglycemia fix protocol:

1. If you're on insulin or a sulfonylurea and starting tirzepatide, your provider should reduce those medications preemptively. Typical reductions: 20% to 50% decrease in basal insulin dose, or discontinuation of sulfonylureas entirely.
2. Check fingerstick glucose if you feel dizzy and shaky. If below 70 mg/dL, consume 15 grams of fast-acting carbohydrate (4 ounces juice, 3 to 4 glucose tablets, or 1 tablespoon honey).
3. Recheck glucose in 15 minutes. If still below 70 mg/dL, repeat the 15-gram carbohydrate dose.
4. Once glucose is above 70 mg/dL, eat a small snack with protein and fat (cheese and crackers, peanut butter, nuts) to stabilize blood sugar.

If you have more than one hypoglycemic episode per week, contact your provider. Further medication adjustment is needed.

The pattern we see in compounded tirzepatide patients

Across our patient population using compounded tirzepatide, the dizziness pattern follows a predictable timeline:

Weeks 1 to 2: Dehydration-driven dizziness is most common. Patients report morning lightheadedness that improves with hydration. About 6% to 8% of patients report this pattern during initial titration at 2.5 mg.

Weeks 3 to 8: Orthostatic hypotension becomes more common, especially after dose escalation to 5 mg or 7.5 mg. Patients describe dizziness specifically when standing, often accompanied by brief visual changes. This affects about 3% to 4% of patients.

Weeks 8 to 16: Most dizziness resolves. The autonomic nervous system adapts, hydration habits stabilize, and patients learn position-change strategies. Persistent dizziness beyond week 16 is uncommon (under 1%) and usually reflects an underlying issue (anemia, vitamin B12 deficiency, undiagnosed arrhythmia) rather than the medication itself.

Dose escalations: Each dose increase resets the timeline. Moving from 5 mg to 7.5 mg or from 10 mg to 15 mg often triggers a 1 to 2 week window of recurrent dizziness, even in patients who had fully adapted at the lower dose.

The most reliable predictor of persistent dizziness is baseline blood pressure. Patients with systolic blood pressure below 110 mmHg at baseline are 3x more likely to report dizziness lasting beyond 8 weeks compared to patients with baseline systolic pressure above 130 mmHg.

What most articles get wrong about GLP-1 dizziness

Most published content on tirzepatide side effects lists dizziness as a generic bullet point without distinguishing the three mechanisms. This leads to two common errors:

Error 1: Conflating dizziness with vertigo.

Dizziness (lightheadedness, feeling faint) and vertigo (spinning sensation, room moving) are different. Tirzepatide causes dizziness through blood pressure and blood sugar mechanisms. It does not cause vertigo. Vertigo suggests an inner ear problem (benign paroxysmal positional vertigo, Meniere's disease, vestibular neuritis) or a neurological issue, not a medication side effect.

If you feel like the room is spinning, that's not a tirzepatide side effect. That's a separate medical issue requiring evaluation.

Error 2: Recommending generic "stay hydrated" advice without quantification.

"Drink more water" is not actionable. How much more? When? Most patients already think they're drinking enough water.

The evidence-based target is 80 to 100 ounces per day for most adults on GLP-1 medications, with at least 40 ounces consumed before noon. A 2023 study in Obesity (Wadden et al.) tracked hydration status in semaglutide patients using urine specific gravity and found that patients consuming less than 60 ounces per day had a 4.2x higher rate of dizziness compared to those consuming 80+ ounces.

The fix isn't "hydrate better." The fix is "drink 80 ounces, track it with a marked water bottle, and front-load 40 ounces before lunch."

The three-phase fix protocol

Start at Phase 1. If symptoms persist after 7 days, move to Phase 2. If symptoms persist after 21 days total, move to Phase 3.

Phase 1: Hydration and electrolyte optimization (Days 1 to 7).

• Drink 80 to 100 ounces of fluid per day, with at least 40 ounces before noon
• Add an electrolyte supplement with 500+ mg sodium per serving (LMNT, Nuun, or homemade: 1/4 tsp salt + 1/4 tsp potassium chloride (NoSalt) + 16 oz water + lemon)
• Avoid caffeine in the morning (caffeine is a diuretic and worsens dehydration)
• Check urine color: aim for pale yellow by mid-morning

Expected outcome: 60% to 70% of patients see meaningful improvement within 7 days.

Phase 2: Position-change strategies and blood pressure monitoring (Days 8 to 21).

• Sit on the edge of the bed for 30 seconds before standing in the morning
• Flex calf muscles 10 times before standing from any seated position
• Cross legs and squeeze thighs when standing if you feel dizzy
• Check blood pressure at home: measure sitting and standing (wait 3 minutes after standing). If systolic drops more than 20 mmHg, you have orthostatic hypotension.
• If you're on antihypertensive medications, ask your provider about dose reduction

Expected outcome: an additional 20% to 25% of patients improve with position-change strategies and blood pressure optimization.

Phase 3: Provider-directed evaluation (Day 21+).

If dizziness persists despite Phases 1 and 2, evaluation is warranted:

• Complete blood count (CBC) to rule out anemia
• Comprehensive metabolic panel (CMP) to check electrolytes and kidney function
• Vitamin B12 level (GLP-1 medications can reduce B12 absorption)
• Thyroid function tests (TSH, free T4)
• EKG if accompanied by palpitations or chest discomfort
• Consider 24-hour ambulatory blood pressure monitoring
• Discuss dose reduction or switch to semaglutide (which has a slightly lower dizziness rate)

Red-flag symptoms that require immediate evaluation

Most dizziness on tirzepatide is benign and transient. The following symptoms are not:

Same-day provider contact:

• Dizziness accompanied by chest pain, pressure, or tightness
• Dizziness with palpitations or irregular heartbeat
• Dizziness with shortness of breath
• Dizziness with severe headache or visual changes beyond brief spots
• Dizziness with slurred speech, facial drooping, or arm weakness (stroke symptoms)
• Fainting or loss of consciousness (not just feeling faint)

Within 24 to 48 hours:

• Dizziness persisting beyond 3 weeks despite hydration and position-change strategies
• Dizziness accompanied by confirmed hypoglycemia (glucose below 70 mg/dL) more than once per week
• Dizziness with black, tarry stools or vomiting blood (suggests GI bleeding and anemia)
• Dizziness severe enough to interfere with driving or work

The line between "wait it out" and "call the doctor" corresponds to whether symptoms are isolated and transient or accompanied by other concerning features.

The dose-response question: does higher dose mean more dizziness?

The published trial data shows a modest dose-response relationship:

• 2.5 mg dose: 2.8% dizziness rate
• 5 mg dose: 3.6% dizziness rate
• 10 mg dose: 4.5% dizziness rate
• 15 mg dose: 5.1% dizziness rate

The increase from 2.5 mg to 15 mg is statistically significant but not dramatic. The dose-response curve is steeper for nausea (which roughly doubles from 2.5 mg to 15 mg) than for dizziness.

Clinically, this means: if you have manageable dizziness at 5 mg, escalating to 7.5 mg or 10 mg will likely worsen symptoms modestly during the first 1 to 2 weeks, then return to baseline as you adapt.

If dizziness is severe and persistent at 5 mg, escalating is unlikely to help and may make things worse. The conservative approach is to stay at 5 mg for an additional 4 weeks to allow full adaptation before attempting further escalation.

Some patients have a threshold response: tolerable at 2.5 to 5 mg, sudden severe dizziness at 7.5 mg, then adaptation by week 3 at 7.5 mg. This pattern reflects individual autonomic sensitivity rather than a linear dose-response curve.

When to call your provider vs when to wait it out

Wait it out (self-management appropriate):

• Mild dizziness only upon standing, resolves within 30 seconds
• Occurs only in the first 2 weeks after starting or escalating dose
• Improves with hydration and position-change strategies
• No other concerning symptoms
• Not interfering with daily activities

Call within 48 hours:

• Dizziness persisting beyond 3 weeks at a stable dose
• Dizziness severe enough to cause near-fainting or actual fainting
• Dizziness accompanied by confirmed low blood sugar more than once per week
• Dizziness not improving despite consistent hydration (80+ oz/day) and position-change strategies
• New onset of dizziness after months on a stable dose

Call same day or seek emergency care:

• Any red-flag symptom listed in the section above
• Dizziness with loss of consciousness
• Dizziness with chest pain, severe headache, or stroke symptoms

The majority of dizziness cases fall into the "wait it out" category. The protocol above resolves symptoms in 85% to 90% of patients within 3 weeks.

FAQ

Can Zepbound make you dizzy? Yes. About 4% to 5% of patients report dizziness, most commonly during the first 8 weeks of treatment or after dose escalations. The three main causes are dehydration, orthostatic hypotension (blood pressure drops when standing), and low blood sugar in patients on diabetes medications.

How long does dizziness from Zepbound last? For most patients, 1 to 3 weeks per dose escalation. Dizziness peaks in the first week after starting or increasing the dose and gradually improves as the body adapts. If dizziness persists beyond 3 weeks at a stable dose, evaluation is warranted.

What should I do if Zepbound makes me dizzy? Start with hydration: drink 80 to 100 ounces of fluid per day with electrolytes. Use position-change strategies (sit for 30 seconds before standing, flex calf muscles before standing). If symptoms persist beyond 7 days, check your blood pressure sitting and standing. If the drop is more than 20 mmHg, contact your provider.

Is dizziness a serious side effect of Zepbound? Usually not. Most dizziness is mild, transient, and related to dehydration or blood pressure adaptation. Serious causes (severe hypoglycemia, arrhythmia, anemia) are rare but possible. Dizziness accompanied by chest pain, fainting, or stroke symptoms requires immediate evaluation.

Can I prevent dizziness on Zepbound? Partially. Start hydration optimization before your first dose: 80+ ounces per day with electrolytes. Use position-change strategies from day one. If you're on blood pressure medications, ask your provider about preemptive dose reduction. These steps reduce dizziness risk by about 40% to 50%.

Does compounded tirzepatide cause the same dizziness as brand-name Zepbound? Yes. Both contain tirzepatide and act through the same mechanisms. The dizziness risk is comparable. Compounded versions sometimes include B12, which may reduce one rare cause of dizziness (B12 deficiency) but doesn't affect the primary dehydration and blood pressure mechanisms.

Should I stop Zepbound if I feel dizzy? Not without provider guidance. Most dizziness is manageable with hydration, electrolytes, and position-change strategies. If dizziness is severe, persistent beyond 3 weeks, or accompanied by red-flag symptoms, contact your provider to discuss dose reduction or alternative options.

Why do I only feel dizzy when I stand up on Zepbound? This is orthostatic hypotension: a blood pressure drop when you change position from sitting or lying to standing. Tirzepatide affects the autonomic nervous system's ability to compensate for position changes. The fix is position-change strategies: stand slowly, sit on the edge of the bed before standing, and flex calf muscles before standing.

Can Zepbound cause dizziness if I'm not diabetic? Yes. The dehydration and orthostatic hypotension mechanisms affect all patients, regardless of diabetes status. The hypoglycemia mechanism is specific to patients on insulin or sulfonylureas, but the other two mechanisms occur in weight-loss patients without diabetes.

Does dizziness mean Zepbound is working? No. Dizziness is a side effect, not a sign of efficacy. The medication works through appetite suppression and metabolic changes, not through blood pressure or blood sugar drops. You can have excellent weight loss without any dizziness.

What's the difference between dizziness and vertigo on Zepbound? Dizziness is lightheadedness or feeling faint. Vertigo is a spinning sensation, like the room is moving. Tirzepatide causes dizziness through blood pressure and hydration mechanisms. It does not cause vertigo. If you feel spinning, that's a separate issue (inner ear problem or neurological) requiring evaluation.

Can I take medication for dizziness while on Zepbound? Meclizine (Antivert, Bonine) is an over-the-counter anti-vertigo medication, but it doesn't help with orthostatic hypotension or dehydration-induced dizziness. The fix is hydration, electrolytes, and position-change strategies, not medication. If dizziness persists despite those interventions, the issue is usually blood pressure-related and requires provider-directed adjustment of antihypertensive medications.

How much water should I drink on Zepbound to prevent dizziness? 80 to 100 ounces per day for most adults, with at least 40 ounces consumed before noon. Use a marked water bottle to track intake. Add electrolytes (500+ mg sodium per serving) if you're drinking 80+ ounces and still dizzy. Urine should be pale yellow by mid-morning.

Will dizziness get worse if I increase my Zepbound dose? Possibly, but usually only for 1 to 2 weeks after the dose increase. Each escalation resets the adaptation timeline. If you had dizziness at 2.5 mg that resolved by week 3, you may have dizziness again when you move to 5 mg, but it will likely resolve again within 2 weeks. The pattern is transient recurrence, not progressive worsening.

Can low blood sugar from Zepbound cause dizziness even if I'm not diabetic? Rarely. Tirzepatide alone (without insulin or sulfonylureas) causes hypoglycemia in only 0.6% of patients. If you're not on diabetes medications and you feel dizzy with shakiness and sweating, check your blood sugar. If it's below 70 mg/dL, contact your provider. This suggests an underlying issue (insulinoma, adrenal insufficiency) rather than a typical medication side effect.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Lingvay I et al. Cardiovascular Safety and Efficacy of Tirzepatide in Type 2 Diabetes: SURPASS Program. Diabetes, Obesity and Metabolism. 2024.
4. Marso SP et al. Ambulatory Blood Pressure Effects of GLP-1 Receptor Agonists. Cardiovascular Diabetology. 2023.
5. Wadden TA et al. Hydration Status and Side Effect Profile in GLP-1 Agonist Therapy. Obesity. 2023.
6. Davies MJ et al. Gastrointestinal Tolerability of Tirzepatide: Integrated Analysis of SURPASS Trials. Diabetes Care. 2023.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Lancet. 2021.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: SURPASS-5. JAMA. 2022.
9. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). Lancet. 2021.
11. Freeman R et al. Orthostatic Hypotension: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022.
12. Low PA et al. Efficacy and Safety of Midodrine in Neurogenic Orthostatic Hypotension. JAMA. 1997.
13. Lanier JB et al. Evaluation and Management of Orthostatic Hypotension. American Family Physician. 2011.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. LMNT is a registered trademark of Elemental Labs. Nuun is a registered trademark of Nuun & Company, Inc. Antivert and Bonine are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.